Review

Effect of glucose-insulin-potassium infusion on mortality in critical care settings: A systematic review and meta-analysis

Michael A. Puskarich, Michael S. Runyon, Stephen Trzeciak, Jeffrey Kline, Alan E. Jones

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This study seeks to measure the treatment effect of glucose-insulin- potassium (GIK) infusion on mortality in critically ill patients. A systematic review of randomized controlled trials is conducted, comparing GIK treatment with standard care or placebo in critically ill adult patients. The primary outcome variable is mortality. Two authors independently extract data and assess study quality. The primary analysis is based on the random effects model to produce pooled odds ratios (ORs) with 95% confidence intervals (CIs). The search yields 1720 potential publications; 23 studies are included in the final analysis, providing a sample of 22 525 patients. The combined results demonstrate no heterogeneity (P =.57, I 2 = 0%) and no effect on mortality (OR = 1.02; 95% CI, 0.93-1.11) with GIK treatment. No experimental studies of shock or sepsis populations are identified. This meta-analysis finds that there is no mortality benefit to GIK infusion in critically ill patients; however, study populations are limited to acute myocardial infarction and cardiovascular surgery patients. No studies are identified using GIK in patients with septic shock or other forms of circulatory shock, providing an absence of evidence regarding the effect of GIK as a therapy in patients with shock.

Original languageEnglish (US)
Pages (from-to)758-767
Number of pages10
JournalJournal of Clinical Pharmacology
Volume49
Issue number7
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Critical Care
Meta-Analysis
Potassium
Insulin
Glucose
Mortality
Critical Illness
Shock
Odds Ratio
Confidence Intervals
Therapeutics
Septic Shock
Population
Publications
Sepsis
Randomized Controlled Trials
Myocardial Infarction
Placebos

Keywords

  • Anesthesiology
  • Clinical research
  • Clinical trials
  • Critical care
  • Emergency medicine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Review : Effect of glucose-insulin-potassium infusion on mortality in critical care settings: A systematic review and meta-analysis. / Puskarich, Michael A.; Runyon, Michael S.; Trzeciak, Stephen; Kline, Jeffrey; Jones, Alan E.

In: Journal of Clinical Pharmacology, Vol. 49, No. 7, 07.2009, p. 758-767.

Research output: Contribution to journalArticle

Puskarich, Michael A. ; Runyon, Michael S. ; Trzeciak, Stephen ; Kline, Jeffrey ; Jones, Alan E. / Review : Effect of glucose-insulin-potassium infusion on mortality in critical care settings: A systematic review and meta-analysis. In: Journal of Clinical Pharmacology. 2009 ; Vol. 49, No. 7. pp. 758-767.
@article{ad6de9799e6e4f2382737249b72ecdc2,
title = "Review: Effect of glucose-insulin-potassium infusion on mortality in critical care settings: A systematic review and meta-analysis",
abstract = "This study seeks to measure the treatment effect of glucose-insulin- potassium (GIK) infusion on mortality in critically ill patients. A systematic review of randomized controlled trials is conducted, comparing GIK treatment with standard care or placebo in critically ill adult patients. The primary outcome variable is mortality. Two authors independently extract data and assess study quality. The primary analysis is based on the random effects model to produce pooled odds ratios (ORs) with 95{\%} confidence intervals (CIs). The search yields 1720 potential publications; 23 studies are included in the final analysis, providing a sample of 22 525 patients. The combined results demonstrate no heterogeneity (P =.57, I 2 = 0{\%}) and no effect on mortality (OR = 1.02; 95{\%} CI, 0.93-1.11) with GIK treatment. No experimental studies of shock or sepsis populations are identified. This meta-analysis finds that there is no mortality benefit to GIK infusion in critically ill patients; however, study populations are limited to acute myocardial infarction and cardiovascular surgery patients. No studies are identified using GIK in patients with septic shock or other forms of circulatory shock, providing an absence of evidence regarding the effect of GIK as a therapy in patients with shock.",
keywords = "Anesthesiology, Clinical research, Clinical trials, Critical care, Emergency medicine",
author = "Puskarich, {Michael A.} and Runyon, {Michael S.} and Stephen Trzeciak and Jeffrey Kline and Jones, {Alan E.}",
year = "2009",
month = "7",
doi = "10.1177/0091270009334375",
language = "English (US)",
volume = "49",
pages = "758--767",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Review

T2 - Effect of glucose-insulin-potassium infusion on mortality in critical care settings: A systematic review and meta-analysis

AU - Puskarich, Michael A.

AU - Runyon, Michael S.

AU - Trzeciak, Stephen

AU - Kline, Jeffrey

AU - Jones, Alan E.

PY - 2009/7

Y1 - 2009/7

N2 - This study seeks to measure the treatment effect of glucose-insulin- potassium (GIK) infusion on mortality in critically ill patients. A systematic review of randomized controlled trials is conducted, comparing GIK treatment with standard care or placebo in critically ill adult patients. The primary outcome variable is mortality. Two authors independently extract data and assess study quality. The primary analysis is based on the random effects model to produce pooled odds ratios (ORs) with 95% confidence intervals (CIs). The search yields 1720 potential publications; 23 studies are included in the final analysis, providing a sample of 22 525 patients. The combined results demonstrate no heterogeneity (P =.57, I 2 = 0%) and no effect on mortality (OR = 1.02; 95% CI, 0.93-1.11) with GIK treatment. No experimental studies of shock or sepsis populations are identified. This meta-analysis finds that there is no mortality benefit to GIK infusion in critically ill patients; however, study populations are limited to acute myocardial infarction and cardiovascular surgery patients. No studies are identified using GIK in patients with septic shock or other forms of circulatory shock, providing an absence of evidence regarding the effect of GIK as a therapy in patients with shock.

AB - This study seeks to measure the treatment effect of glucose-insulin- potassium (GIK) infusion on mortality in critically ill patients. A systematic review of randomized controlled trials is conducted, comparing GIK treatment with standard care or placebo in critically ill adult patients. The primary outcome variable is mortality. Two authors independently extract data and assess study quality. The primary analysis is based on the random effects model to produce pooled odds ratios (ORs) with 95% confidence intervals (CIs). The search yields 1720 potential publications; 23 studies are included in the final analysis, providing a sample of 22 525 patients. The combined results demonstrate no heterogeneity (P =.57, I 2 = 0%) and no effect on mortality (OR = 1.02; 95% CI, 0.93-1.11) with GIK treatment. No experimental studies of shock or sepsis populations are identified. This meta-analysis finds that there is no mortality benefit to GIK infusion in critically ill patients; however, study populations are limited to acute myocardial infarction and cardiovascular surgery patients. No studies are identified using GIK in patients with septic shock or other forms of circulatory shock, providing an absence of evidence regarding the effect of GIK as a therapy in patients with shock.

KW - Anesthesiology

KW - Clinical research

KW - Clinical trials

KW - Critical care

KW - Emergency medicine

UR - http://www.scopus.com/inward/record.url?scp=67650475389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650475389&partnerID=8YFLogxK

U2 - 10.1177/0091270009334375

DO - 10.1177/0091270009334375

M3 - Article

VL - 49

SP - 758

EP - 767

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -